SG11201810871WA - Methods of producing modified natural killer cells and methods of use - Google Patents

Methods of producing modified natural killer cells and methods of use

Info

Publication number
SG11201810871WA
SG11201810871WA SG11201810871WA SG11201810871WA SG11201810871WA SG 11201810871W A SG11201810871W A SG 11201810871WA SG 11201810871W A SG11201810871W A SG 11201810871WA SG 11201810871W A SG11201810871W A SG 11201810871WA SG 11201810871W A SG11201810871W A SG 11201810871WA
Authority
SG
Singapore
Prior art keywords
cells
methods
international
bethesda
population
Prior art date
Application number
SG11201810871WA
Other languages
English (en)
Inventor
Richard Childs
Dhanalakshmi Chinnasamy
David Allan
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of SG11201810871WA publication Critical patent/SG11201810871WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/505—CD4; CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1135—Granulocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201810871WA 2016-07-25 2017-07-25 Methods of producing modified natural killer cells and methods of use SG11201810871WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662366493P 2016-07-25 2016-07-25
PCT/US2017/043774 WO2018022646A1 (en) 2016-07-25 2017-07-25 Methods of producing modified natural killer cells and methods of use

Publications (1)

Publication Number Publication Date
SG11201810871WA true SG11201810871WA (en) 2019-01-30

Family

ID=59656171

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201810871WA SG11201810871WA (en) 2016-07-25 2017-07-25 Methods of producing modified natural killer cells and methods of use
SG11202003201QA SG11202003201QA (en) 2016-07-25 2018-11-01 Methods of producing modified natural killer cells and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11202003201QA SG11202003201QA (en) 2016-07-25 2018-11-01 Methods of producing modified natural killer cells and methods of use

Country Status (7)

Country Link
US (2) US11293010B2 (enExample)
EP (2) EP3487991B1 (enExample)
JP (2) JP7086928B2 (enExample)
CN (2) CN109844099B (enExample)
IL (1) IL273979B2 (enExample)
SG (2) SG11201810871WA (enExample)
WO (2) WO2018022646A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101520534B1 (ko) 2012-05-07 2015-05-21 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
US10813952B2 (en) * 2014-11-14 2020-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
US12516292B2 (en) 2016-07-25 2026-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing modified natural killer cells and methods of use
EP3487991B1 (en) 2016-07-25 2022-09-07 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of producing modified natural killer cells and methods of use
WO2018104554A1 (en) * 2016-12-09 2018-06-14 Onkimmune Limited Improved nk-based cell therapy
AU2018219895C1 (en) 2017-02-09 2024-10-03 Indapta Therapeutics, Inc. Engineered Natural Killer (NK) cells and compositions and methods thereof
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
CN115710576A (zh) 2018-02-01 2023-02-24 Nkmax有限公司 产生天然杀伤细胞的方法和用于治疗癌症的组合物
JP7360174B2 (ja) * 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
SG11202008008UA (en) * 2018-02-21 2020-09-29 Univ Texas Universal antigen presenting cells and uses thereof
GB201804701D0 (en) * 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
AU2019271366B2 (en) * 2018-05-16 2026-02-26 Research Institute At Nationwide Children's Hospital Generation of knock-out primary and expanded human NK cells using Cas9 ribonucleoproteins
CN112512573B (zh) * 2018-05-23 2026-02-27 百提威生技股份有限公司 双特异性t细胞衔接蛋白及其用途
US12304962B2 (en) 2018-05-30 2025-05-20 Glycostem Therapeutics B.V. CAR NK cells
US12692308B2 (en) 2018-06-06 2026-07-28 Stemcell Technologies Canada Inc. Kits, compositions and methods for cell enrichment
KR102907902B1 (ko) 2018-08-01 2026-01-02 난트퀘스트, 인크. 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템
SG11202102012SA (en) * 2018-08-28 2021-04-29 Pharos Vaccine Inc Improved lentiviral vector
KR20210063348A (ko) * 2018-08-28 2021-06-01 이뮤노테크 바이오팜 씨오., 엘티디. 개선된 치료용 t 세포
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
CN110511912B (zh) * 2018-08-30 2024-03-22 浙江煦顼技术有限公司 免疫细胞的功能调节
EP3864160A4 (en) * 2018-10-10 2022-10-26 Wisconsin Alumni Research Foundation KIR 7.1 GENE THERAPY VECTORS AND METHODS OF USING THE SAME
CN109402053A (zh) * 2018-10-17 2019-03-01 广州元帅生物科技有限公司 一种外周血来源单个核细胞的分离及诱导培养方法
EP3884041A2 (en) * 2018-11-21 2021-09-29 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
CN113710691B (zh) 2019-02-20 2025-03-04 罗格斯新泽西州立大学 自然杀伤和嵌合抗原受体修饰的细胞的扩增
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
KR20200110576A (ko) * 2019-03-15 2020-09-24 재단법인대구경북과학기술원 사이토카인 기반 면역세포 및 그의 면역 치료 용도
CN113710697A (zh) 2019-03-15 2021-11-26 美国政府(由卫生和人类服务部的部长所代表) 嵌合衔接子和激酶信号传导蛋白及其在免疫疗法中的用途
EP3712257A1 (en) * 2019-03-21 2020-09-23 ONK Therapeutics Limited Modified natural killer cells with increased resistance to cell death
JP2022526504A (ja) * 2019-03-21 2022-05-25 オーエヌケー セラピューティクス リミテッド 細胞死に対する耐性が増大した改変免疫エフェクター細胞
CN110079529A (zh) * 2019-04-28 2019-08-02 成都美杰赛尔生物科技有限公司 用于靶向敲除人NKG2A/KLRC1基因的sgRNA、表达载体、试剂盒及其用途
CN110106202A (zh) * 2019-05-07 2019-08-09 杭州师范大学 抗肿瘤nk细胞的制备方法及其细胞与应用
CA3143198A1 (en) * 2019-06-14 2020-12-17 G Tech Bio Llc Activated lymphocytic cells and methods of using the same to treat cancer and infectious conditions
CN110205293A (zh) * 2019-06-25 2019-09-06 中冠赛尔生物科技(北京)有限公司 一种加强型高效治疗肺癌的nk免疫细胞的制备方法及应用
US20210077527A1 (en) * 2019-09-13 2021-03-18 The Research Institute At Nationwide Children's Hospital Universal donor selection method to identify nk-cell-donors
US20220347216A1 (en) * 2019-09-13 2022-11-03 Ohio State Innovation Foundation Nk cell immunotherapy compositions, methods of making and methods of using same
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
AU2020437669A1 (en) 2020-03-26 2022-09-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services CD28H domain-containing chimeric antigen receptors and methods of use
CN113528452B (zh) * 2020-07-06 2023-06-06 上海鑫湾生物科技有限公司 共表达IL-21和hrCD16嵌合受体的免疫细胞及其应用
IL300903A (en) * 2020-09-02 2023-04-01 Nkarta Inc Expansion and enhanced cytotoxicity of natural killer cells and their uses
EP3964265A1 (en) * 2020-09-07 2022-03-09 Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof
CN112029721A (zh) * 2020-09-09 2020-12-04 广东昭泰体内生物医药科技有限公司 一种活性增强型nk细胞的制备方法
KR102581230B1 (ko) * 2020-10-16 2023-09-21 의료법인 성광의료재단 항암 관련 유전자 발현이 조절된 자연살해세포 및 이의 용도
EP4240829A1 (en) 2020-11-04 2023-09-13 The United States of America, as represented by the Secretary, Department of Health and Human Services Modified nk cells with reduced ccr5 expression and methods of their use
US20240197783A1 (en) * 2021-04-21 2024-06-20 Indapta Therapeutics, Inc. Methods of treatment and dosing of natural killer cell compositions
CN115505572B (zh) * 2021-06-22 2025-11-14 康立泰生物医药(青岛)有限公司 一种增强型抗肿瘤nk细胞及其制备方法和应用
CA3228692A1 (en) * 2021-08-30 2023-03-09 Edward L. Perkins Tcd34 and other markers for identification and sorting of cells and for use as in vivo tracking assistant
WO2023044304A1 (en) 2021-09-15 2023-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
CN114306606B (zh) * 2021-11-29 2023-05-26 江苏省人民医院（南京医科大学第一附属医院） cGAS抑制剂在制备治疗T细胞淋巴瘤的药物中的应用
CN114381434A (zh) * 2022-01-17 2022-04-22 华东师范大学 一种趋化型car-nk细胞及其制备方法和应用
CN114807237A (zh) * 2022-05-12 2022-07-29 广东普罗凯融生物医药科技有限公司 一种过表达CD16a的NK细胞的制备方法及其应用
CN115074325A (zh) * 2022-07-07 2022-09-20 广州希灵生物科技有限公司 Herceptin联合4-1BBL体外扩增NK方法
CN115466726B (zh) * 2022-09-05 2023-09-19 北京景达生物科技有限公司 一种nk细胞的高效基因转导方案
CN116178566A (zh) * 2022-09-30 2023-05-30 深圳博雅感知药业有限公司 靶向cd33的嵌合抗原受体和制备b16-cd33 car-nk细胞的方法
CN115975922B (zh) * 2022-12-15 2024-06-28 杭州师范大学 Bx795在制备nk-92细胞激活剂上的应用
WO2024131685A1 (zh) * 2022-12-19 2024-06-27 苏州沙砾生物科技有限公司 一种细胞培养方法及其用途
WO2024261045A1 (en) 2023-06-20 2024-12-26 Zelluna Immunotherapy As Methods of enhancing or modifying nk cells
WO2025232819A1 (en) * 2024-05-08 2025-11-13 Qihan Hong Kong Limited Immunotherapies using engineered cells for enhanced bone marrow homing
EP4692325A1 (en) * 2024-08-07 2026-02-11 Miltenyi Biotec B.V. & Co. KG Method for generation of a composition comprising natural killer cells

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177551A1 (en) * 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
DE10019075B4 (de) * 2000-04-18 2007-01-18 Vision 7 Gmbh Verwendung von CD34 oder einem davon abgeleiteten Polypeptid als Zell-Oberflächen- bzw. Gentransfer-Marker
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
JP5525689B2 (ja) 2004-11-02 2014-06-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 過剰増殖性障害を処置するための組成物および方法
CN101356679A (zh) * 2005-10-31 2009-01-28 昂考梅德药品有限公司 用于诊断和治疗癌症的组合物和方法
US20070264687A1 (en) * 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
CN101684456A (zh) * 2008-09-28 2010-03-31 江门罗森生物制药有限公司 一种体外培养条件下扩增人nk细胞的方法
EP3546583A1 (en) * 2009-06-17 2019-10-02 Tocagen Inc. Producer cells for replication competent retroviral vectors
RU2729401C2 (ru) * 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
EP2793026A1 (en) * 2013-04-18 2014-10-22 Centre National de la Recherche Scientifique (CNRS) New method for monitoring cancer and/or inflammatory reaction based on relb phosphorylation
DK2992020T3 (da) * 2013-05-03 2020-02-10 Ohio State Innovation Foundation Cs1-specifik kimær antigenreceptor-manipulerede immuneffektorceller
WO2015112793A2 (en) * 2014-01-27 2015-07-30 St. Jude Children's Research Hospital, Inc. Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof
WO2016073595A1 (en) 2014-11-05 2016-05-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services T cells and dendritic cells for polyomavirus therapy
US10813952B2 (en) 2014-11-14 2020-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
WO2016085946A1 (en) * 2014-11-24 2016-06-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Active cxcr4+ immune cells and methods for their production and use
US12533338B2 (en) * 2015-09-30 2026-01-27 Vycellix, Inc. Enhanced gene delivery to natural killer cells, hematopoietic stem cells and macrophages
CN105567634A (zh) * 2016-01-27 2016-05-11 上海润泉生物技术有限公司 一种用于nk细胞体外扩增的培养基及nk细胞体外扩增的方法
EP3487991B1 (en) 2016-07-25 2022-09-07 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of producing modified natural killer cells and methods of use
US12516292B2 (en) * 2016-07-25 2026-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing modified natural killer cells and methods of use
CN106350487B (zh) * 2016-09-13 2019-01-25 北京多赢时代转化医学研究院 联合制备car-nk细胞和car-nkt细胞的方法
KR20240024328A (ko) * 2016-11-22 2024-02-23 알로플렉스 바이오테라퓨틱스 동종이형 종양 세포 백신

Also Published As

Publication number Publication date
CN109844099A (zh) 2019-06-04
SG11202003201QA (en) 2020-05-28
US11293010B2 (en) 2022-04-05
JP2019523001A (ja) 2019-08-22
JP7364559B2 (ja) 2023-10-18
EP3487991B1 (en) 2022-09-07
IL273979B2 (en) 2024-09-01
IL273979B1 (en) 2024-05-01
WO2018022646A1 (en) 2018-02-01
US20220228117A1 (en) 2022-07-21
CN109844099B (zh) 2024-01-02
CN111344395A (zh) 2020-06-26
CN111344395B (zh) 2024-07-02
JP7086928B2 (ja) 2022-06-20
EP3704231A1 (en) 2020-09-09
EP3487991A1 (en) 2019-05-29
US20180057795A1 (en) 2018-03-01
WO2019089955A1 (en) 2019-05-09
IL273979A (en) 2020-05-31
US12448604B2 (en) 2025-10-21
JP2021501578A (ja) 2021-01-21

Similar Documents

Publication Publication Date Title
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201806002SA (en) Methods for extending the replicative capacity of somatic cells during an ex vivo cultivation process
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201806340YA (en) Zika virus vaccine
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201908658TA (en) Nucleobase editors comprising nucleic acid programmable dna binding proteins
SG11201805162VA (en) Plasmid constructs for heterologous protein expression and methods of use
SG11201811432WA (en) Rna for cancer therapy
SG11201903407XA (en) Secretable variant immunomodulatory proteins and engineered cell therapy
SG11201805229YA (en) Means and methods for treating hbv
SG11201906301UA (en) Methods of manufacture of nut flours and formulations for oral immunotherapy
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201909203WA (en) Tissue selective transgene expression
SG11201807269PA (en) Filamentous fungal biomats, methods of their production and methods of their use
SG11201809041TA (en) Compositions and methods for selective protein expression
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201908088RA (en) Antibodies against pd-l1
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201809700YA (en) Gdf15 fusion proteins and uses thereof
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201807022XA (en) Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
SG11201810975UA (en) Method for stabilizing proteins